Guerra et al. show that combined MEK and BET inhibitors are effective in ∼50% of KRAS-mutant NSCLC. HOXC10 is a biomarker of response and regulates expression of pre-replication complex proteins in conjunction with MEK. MEK/BET inhibitors suppress HOXC10 to trigger replication defects and induce cell death.
from Cancer Cell https://ift.tt/2wbhjZa
from Cancer Cell https://ift.tt/2wbhjZa